Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review.
adverse effects of oncologic drugs
drug-induced sweet syndrome
neutrophilic dermatosis
sweet syndrome
targeted anticancer therapy
tyrosine kinase inhibitor
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
24
09
2020
accepted:
23
10
2020
pubmed:
29
10
2020
medline:
25
5
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
Tyrosine kinase inhibitors are a class of targeted anticancer drugs that inhibit cancer cell proliferation by inactivating proteins involved in signal transduction cascades. Various cutaneous adverse events have been observed after tyrosine kinase inhibitor administration, including Sweet syndrome. We queried the PubMed database to identify 14 cases of Sweet syndrome thought to be secondary to tyrosine kinase inhibitors. Tyrosine kinase inhibitor-induced Sweet syndrome had a median of 2 months latency following drug administration. All cases but one had morphologic features classic for Sweet syndrome (erythematous and tender papules, plaques, or nodules). All cases also had classic histopathologic findings (dermal neutrophilic infiltrate without vasculitis or necrosis). Using diagnostic criteria for drug-induced Sweet syndrome and the Naranjo Drug Reaction Probability Scale for a drug-induced cutaneous eruption, we found that six cases favored a drug-induced etiology over malignancy, two cases favored a malignancy-associated Sweet syndrome, and the remaining eight met drug-induced Sweet syndrome criteria but had low Naranjo scores. Nine cases resulted in medication discontinuation, while five cases continued anticancer therapy and were treated only with corticosteroids with quick resolution of skin lesions. Dermatologists should be aware of this adverse cutaneous reaction to tyrosine kinase inhibitors and should treat on a case-by-case basis, though limited evidence in this review suggests that oncologic therapy may safely be continued with prompt corticosteroid treatment.
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14461Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36(7):422-439. https://doi.org/10.1016/j.tips.2015.04.005.
Adams JA. Kinetic and catalytic mechanisms of protein kinases. https://doi.org/10.1021/cr000230w
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971-979. https://doi.org/10.1124/jpet.105.084145.
Steeghs N, Nortier JWR, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol. 2007;14(2):942-953. https://doi.org/10.1245/s10434-006-9227-1.
Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48. https://doi.org/10.1186/s12943-018-0804-2.
Pasadyn SR, Knabel D, Fernandez AP, Warren CB. Cutaneous adverse effects of biologic medications. CCJM. 2020;87(5):288-299. https://doi.org/10.3949/ccjm.87a.19119.
Lupu I, Voiculescu N, Bacalbasa N, Cojocaru I, Vrancian V, Giurcaneanu C. Cutaneous complications of molecular targeted therapy used in oncology. J Med Life. 2016;9(1):19-25.
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621-630. https://doi.org/10.1056/NEJMoa1406470.
Li J, Gu J. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;119:50-58. https://doi.org/10.1016/j.critrevonc.2017.09.016.
Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer. 2018;17(2):85-96. https://doi.org/10.1016/j.clcc.2017.12.004.
Guggina LM, Choi AW, Choi JN. EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol Ther. 2017;5(2):135-148. https://doi.org/10.1007/s40487-017-0050-6.
Roujeau JC. Neutrophilic drug eruptions. Clin Dermatol. 2000;18(3):331-337. https://doi.org/10.1016/s0738-081x(99)00124-8.
Kluger N, Marque M, Stoebner P-E, Dandurand M, Meunier L. Possible drug-induced Sweet's syndrome due to trimethoprim-sulfamethoxazole. Acta Derm Venereol. 2008;88(6):637-638. https://doi.org/10.2340/00015555-0516.
Su WP, Liu HN. Diagnostic criteria for Sweet's syndrome. Cutis. 1986;37(3):167-174.
Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013;42(5):1516-1522. https://doi.org/10.3892/ijo.2013.1874.
Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018;78(2):303-309.e4. https://doi.org/10.1016/j.jaad.2017.09.013.
Cohen PR. Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34. https://doi.org/10.1186/1750-1172-2-34.
Cohen PR, Holder WR, Tucker SB, Kono S, Kurzrock R. Sweet syndrome in patients with solid tumors. Cancer. 1993;72(9):2723-2731. https://doi.org/10.1002/1097-0142(19931101)72:9<2723::aid-cncr2820720933>3.0.co;2-f.
von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31(4):535-556; quiz 557-560. https://doi.org/10.1016/s0190-9622(94)70215-2.
Kurzrock R, Cohen PR. Cutaneous paraneoplastic syndromes in solid tumors. Am J Med. 1995;99(6):662-671. https://doi.org/10.1016/s0002-9343(99)80254-x.
Wang JY, French LE, Shear NH, Amiri A, Alavi A. Drug-induced Pyoderma Gangrenosum: a review. Am J Clin Dermatol. 2018;19(1):67-77. https://doi.org/10.1007/s40257-017-0308-7.
Sáez M, García-Bustínduy M, Noda A, et al. Drug-induced Sweet's syndrome. J Eur Acad Dermatol Venereol. 2004;18(2):233-233. https://doi.org/10.1111/j.1468-3083.2004.00866.x.
Thompson DF, Montarella KE. Drug-induced Sweet's syndrome. Annals of Pharmacotherapy. 2016;4:802-811. https://doi.org/10.1345/aph.1H563.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. https://doi.org/10.1038/clpt.1981.154.
Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol. 1996;34(5 Pt 2):918-923. https://doi.org/10.1016/s0190-9622(96)90080-8.
Brody T. Drug class analysis. In: Brody T, ed. FDA's Drug Review Process and the Package Label. London, UK: Academic Press; 2018:441-511. https://doi.org/10.1016/B978-0-12-814647-7.00010-5.
Sharma A, Shah SR, Illum H, Dowell J. Vemurafenib. Drugs. 2012;72(17):2207-2222. https://doi.org/10.2165/11640870-000000000-00000.
Kaune KM, Baumgart M, Gesk S, et al. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells. Arch Dermatol. 2008;144(3):361-364. https://doi.org/10.1001/archderm.144.3.361.
Ainechi S, Carlson JA. Neutrophilic Dermatosis limited to Lipo-Lymphedematous skin in a morbidly obese woman on Dasatinib therapy. Am J Dermatopathol. 2016;38(2):e22-e26. https://doi.org/10.1097/DAD.0000000000000358.
Liu D, Seiter K, Mathews T, Madahar CJ, Ahmed T. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res. 2004;28(1):S61-S63. https://doi.org/10.1016/S0145-2126(03)00257-1.
Sakoda T, Kanamitsu Y, Mori Y, et al. Recurrent subcutaneous Sweet's disease in a Myelofibrosis patient treated with Ruxolitinib before allogeneic stem cell transplantation. Intern Med. 2017;56(18):2481-2485. https://doi.org/10.2169/internalmedicine.8491-16.
Zhang M, Hassan KM, Musiek A, Rosman IS. Ponatinib-induced neutrophilic panniculitis. J Cutan Pathol. 2014;41(7):597-601. https://doi.org/10.1111/cup.12326.
Stewart J, Bayers S, Vandergriff T. Self-limiting Ibrutinib-induced Neutrophilic Panniculitis. Am J Dermatopathol. 2018;40(2):e28-e29. https://doi.org/10.1097/DAD.0000000000000980.
de Masson A, Bouvresse S, Clérici T, Mahé E, Saïag P. Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib. Ann Dermatol Venereol. 2011;138(2):135-139. https://doi.org/10.1016/j.annder.2010.11.009.
Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005;141(3):368-370. https://doi.org/10.1001/archderm.141.3.368.
El Halabi L, Cherif-Rebai K, Michot J-M, Ghez D. Ibrutinib-induced Neutrophilic Dermatosis. Am J Dermatopathol. 2018;40(3):198-200. https://doi.org/10.1097/DAD.0000000000000862.
Yorio JT, Mays SR, Ciurea AM, et al. Case of vemurafenib-induced Sweet's syndrome. J Dermatol. 2014;41(9):817-820. https://doi.org/10.1111/1346-8138.12430.
Matsuda T, Ueda-Hayakawa I, Kambe N, Fujita S, Okamoto H. Sweet syndrome in a patient with chronic myelogenous leukemia under dasatinib treatment. J Dermatol. 2019;46(9):e317-e318. https://doi.org/10.1111/1346-8138.14868.
Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: pathogenesis, sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J American Academy Dermatol. 2018;79(6):987-1006. https://doi.org/10.1016/j.jaad.2017.11.064.
Cohen PR, Kurzrock R. Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol. 2002;3(2):117-131. https://doi.org/10.2165/00128071-200203020-00005.
Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte Colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active Behçet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140(5):570-574. https://doi.org/10.1001/archderm.140.5.570.
Cohen PR, Kurzrock R. Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol. 2000;18(3):265-282. https://doi.org/10.1016/s0738-081x(99)00129-7.
Reuss-Borst MA, Pawelec G, Saal JG, Horny HP, Müller CA, Waller HD. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol. 1993;84(2):356-358. https://doi.org/10.1111/j.1365-2141.1993.tb03083.x.
Yan Z-S, Li D-P, Jiang E-L, et al. Development of sweet syndrome in an acute promyelocyte leukemia patient during treatment with all-trans retinoic acid-case report and literature review. Zhonghua Xue Ye Xue Za Zhi. 2007;28(7):462-465.
Bekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017;127(4):1338-1352. https://doi.org/10.1172/JCI89857.
Kersh AE, Ng S, Chang YM, et al. Targeted therapies: immunologic effects and potential applications outside of cancer. J Clin Pharmacol. 2018;58(1):7-24. https://doi.org/10.1002/jcph.1028.
Scarfì F, Melotti B, Veronesi G, et al. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib. Australasian J Dermatol. 2019;60(3):e242-e243. https://doi.org/10.1111/ajd.13001.
Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, et al. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014;41(3):326-328. https://doi.org/10.1111/cup.12273.
Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen Y-B. FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013;122(2):239-242. https://doi.org/10.1182/blood-2013-01-478172.
Varadarajan N, Boni A, Elder DE, et al. FLT3 inhibitor-associated Neutrophilic Dermatoses. JAMA Dermatol. 2016;152(4):480-482. https://doi.org/10.1001/jamadermatol.2015.6121.